coronary heart disease
Conditions
Interventions
treatment arm:supplementing qi and hemostasis fomula + routine treatment
Control:Pantoprazole Sodium Enteric-Coated Capsules + routine treatment
Sponsors
Wangjing hospital, China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Meet the diagnostic criteria of CHD; 2) Underwent PCI operation successfully; 3) CRUSADE score =41; 4) Be able to sign informed consent.
Exclusion criteria
Exclusion criteria: 1) Use of Warfarin or other agents that might affect platelet aggregation within two weeks; 2) Platelet number <100×10^9/L; 3) Anemia, hemoglobin <100g/L; 4) Active peptic ulcer; 5) Use of PPI within one month; 6) Bleeding tendency or hematological disorders; 7) Pregnant and lactating female; 8) Allergic to component of the test drugs and allergic constitution; 9) Participated to other clinical trial within one month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of MACE;Bleeding events; | — |
Secondary
| Measure | Time frame |
|---|---|
| TCM syndrome score;Thromboelastogram; | — |
Countries
China
Contacts
Public ContactChenhao Zhang
Wangjing hospital, China Academy of Chinese Medical Sciences
Outcome results
None listed